HanchorBio Presents at WIC-APAC 2026: The CD47 Field Enters a New Design Era
Presentation highlights engineered CD47–SIRPα blockade and combination-ready checkpoint design
[Taipei, Shanghai, San Francisco | March 30, 2026] – HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for immuno-oncology and immune-related diseases, today announced that Alvin Luk, PhD, MBA, CCRA, President & Chief Medical Officer (Group) and CEO (USA) of HanchorBio, presented at WIC-APAC 2026 in Taipei on March 29, 2026.
In the presentation, “Reprogramming the CD47-SIRPα Axis in Cancer Immunotherapy: Clinical Validation and Next-Generation Multi-Checkpoint Engineering,” Dr. Luk argued that the CD47 field is now being redefined less by target validation than by therapeutic design. The presentation highlighted a key translational lesson from first-generation CD47 programs: biologic relevance was established, but on-target hematologic toxicity constrained the therapeutic window and limited clinical utility.
Dr. Luk further discussed how engineered SIRPα-Fc approaches may help address that challenge by preserving macrophage-mediated antitumor activity while improving hematologic tolerability, sustaining target engagement, and enabling more clinically usable combination strategies. He also placed this design logic in a broader strategic context, positioning it as a foundation for next-generation multi-checkpoint therapeutics spanning innate and adaptive immunity.
“First-generation CD47 programs helped establish the biologic relevance of the pathway, but they also made clear that hematologic liability was the critical translational barrier,” said Dr. Luk. “The opportunity now is not simply to revisit the mechanism, but to redesign it – preserving meaningful innate immune activity while building molecules with a wider therapeutic window and greater combination potential.”
During the session, Dr. Luk emphasized HanchorBio’s clinical and translational perspective on HCB101, an AI-guided, structurally engineered SIRPα-IgG4 Fc fusion protein designed to selectively block the CD47-SIRPα axis while minimizing hematologic toxicity that limited earlier CD47-directed methods. He also discussed how this work might contribute to the development of broader multi-functional checkpoint programs based on HanchorBio’s Fc-Based Designer Biologics (FBDB™) platform.
WIC-APAC 2026 also marked Dr. Luk’s first presentation of HanchorBio in Taiwan in his current leadership capacity.
Presentation Details
Conference: World Immunotherapy Council Asia-Pacific Conference (WIC-APAC 2026)
Date: March 29, 2026
Location: Taipei, Taiwan
Presentation Title: Reprogramming the CD47-SIRPα Axis in Cancer Immunotherapy: Clinical Validation and Next-Generation Multi-Checkpoint Engineering
This session was moderated by Dr. Peter Mu-Hsin Chang, an attending physician in the Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, and Associate Professor at the Institute of Biopharmaceutical Sciences, National Yang Ming Chiao Tung University. Dr. Chang specializes in head and neck cancer, medical oncology, and immunotherapy-related research, with extensive experience in clinical trials and translational medicine.
Speaker Profile
Dr. Luk is a global biotechnology executive with more than 30 years of leadership experience across translational medicine, clinical development, regulatory strategy, medical affairs, and strategic partnering. His career has focused on advancing innovative therapeutics from early development through global clinical execution, regulatory milestones, and commercialization across the U.S., EU, and Asia. At HanchorBio, he leads global corporate and development strategy and oversees clinical development, regulatory strategy, and medical affairs for the company’s HCB portfolio, including HCB101 and HCB301.
About WIC-APAC
The World Immunotherapy Council (WIC) is an international organization focused on advancing immunotherapy through scientific exchange and global collaboration. WIC-APAC brings together clinical experts, researchers, and healthcare professionals from across the Asia-Pacific region to discuss advances in cancer immunology and immunotherapy.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TPEx) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics with diverse targeting modalities intended to engage both innate and adaptive immune pathways. HanchorBio is advancing a portfolio of differentiated biologics designed to address significant unmet medical needs through rational molecular engineering and scalable CMC strategies.